MedPath

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

Phase 4
Completed
Conditions
Psoriatic Arthritis
Interventions
Registration Number
NCT03151551
Lead Sponsor
Eli Lilly and Company
Brief Summary

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
566
Inclusion Criteria
  • Presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
  • Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints
  • Presence of active plaque psoriasis with a BSA ≥3%
  • Men must agree to use a reliable method of birth control or remain abstinent during the study
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
  • Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
Exclusion Criteria
  • Current or prior use of biologic agents for treatment of Ps or PsA
  • Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
  • Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
  • Serious disorder or illness other than psoriatic arthritis
  • Serious infection within the last 3 months
  • Active Crohn's disease or active ulcerative colitis
  • Active vasculitis or uveitis
  • Diagnosis of or history of malignant disease <5 years prior to randomization
  • Women who are breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AdalimumabAdalimumab80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps. 40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps.
IxekizumabIxekizumab160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants. 80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps. 80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)Week 24

ACR50 response is a ≥50% improvement from baseline for tender joint count(TJC)\& swollen joint count (SJC)\& in at least 3 of the following 5 criteria: Participant's(pts) assessment of joint pain Visual Analog Scale (VAS),Pts Global Assessment of Disease Activity (PatGA)VAS, Physician's Global Assessment of Disease Activity (PGA)VAS, Pts assessment of physical function using the Health Assessment Questionnaire-Disability Index(HAQ-DI), or High Sensitivity(assay)C-Reactive Protein (hs-CRP). PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Pts achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts with active plaque PsO with a BSA≥3% \& PASI=0 at baseline were considered PASI100 responders if they had achieved PASI=0 \& BSA=0 at week 24.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving PASI100Week 24

PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Participants achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Any participants with active plaque psoriasis (PsO) with a BSA ≥3% and PASI = 0 at baseline were considered PASI100 responders if \& only if they had achieved PASI=0 \& BSA=0 at week 24.

Percentage of Participants Achieving ACR50Week 24

ACR50 response is defined as a ≥50% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of joint pain Visual Analog Scale (VAS), Participant's Global Assessment of Disease Activity (PatGA) VAS, Physician's Global Assessment of Disease Activity (PGA) VAS, participant's assessment of physical function using the Health Assessment Questionnaire-Disability Index (HAQ-DI), or High Sensitivity (assay) C-Reactive Protein (hs-CRP).

Trial Locations

Locations (131)

Sir Ganga Ram Hospital

🇮🇳

New Delhi, Delhi, India

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

🇧🇪

Leuven, Belgium

Krishna Institute of Medical Sciences Ltd.

🇮🇳

Secunderabad, Telengana, India

Tel Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Addenbrookes Hospital

🇬🇧

Cambridge, Cambridgeshire, United Kingdom

Government Medical College & Sir Sayajirao General Hospital

🇮🇳

Vadodara, Gujarat, India

Kantonsspital St. Gallen

🇨🇭

St. Gallen, Sankt Gallen, Switzerland

Zentrum für klinische Studien Dr. Ursula Hanusch GmbH

🇦🇹

Wien, Austria

Narayana Hrudayalaya Hospital

🇮🇳

Bangalore, Karnataka, India

Whipps Cross University Hospital

🇬🇧

London, Surrey, United Kingdom

Rambam Medical Center

🇮🇱

Haifa, Israel

Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Arthritis Clinical Research Trial Unit

🇿🇦

Pinelands, Western Cape, South Africa

Barzilai Medical Center

🇮🇱

Ashkelon, Israel

"Dermed" Centrum Medyczne Sp. z o.o.

🇵🇱

Lodz, Poland

Wishaw General Hospital

🇬🇧

Wishaw, North Lanarkshire, United Kingdom

Ruby Hall Clinic and Grant Medical Foundation

🇮🇳

Pune, Maharashtra, India

Royal Cornwall Hospital

🇬🇧

Truro, Cornwall, United Kingdom

Rheumatology, The Queen Elizabeth Hospital

🇦🇺

Woodville South, South Australia, Australia

Atencion Integral en Reumatología

🇦🇷

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

CER Instituto Medico

🇦🇷

Quilmes, Buenos Aires, Argentina

Clinica Adventista de Belgrano

🇦🇷

Ciudad de Buenos Aires, Buenos Aires, Argentina

Hospital Ramos Mejia

🇦🇷

Ciudad Autonoma de Buenos Aire, Argentina

Instituto de Asist Reumatologica Integral

🇦🇷

San Fernando, Buenos Aires, Argentina

Centre hospitalier universitaire Lapeyronie

🇫🇷

Montpellier Cedex 5, France

Southern Clinical Research Pty Ltd

🇦🇺

Hobart, Tasmania, Australia

Nouvel Hôpital Orléans La Source

🇫🇷

Orleans CEDEX 2, France

Instituto Centenario

🇦🇷

Ciudad Autonoma de Buenos Aire, Argentina

CENUDIAB

🇦🇷

Ciudad Autonoma de Buenos Aire, Argentina

Organizacion Medica de Investigacion - OMI

🇦🇷

Ciudad Autonoma de Buenos Aire, Argentina

Reumaclinic

🇧🇪

Genk, Belgium

Universitair Ziekenhuis Gent

🇧🇪

Gent, Belgium

Saint Joseph Hospital

🇧🇪

Gilly, Belgium

Combined Rheumatology Practice (CRP)

🇦🇺

Kogarah, New South Wales, Australia

The Waterside Clinic

🇨🇦

Barrie, Ontario, Canada

Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan

🇦🇷

San Juan, Argentina

Rheuma-Zentrum Wien Oberlaa

🇦🇹

Wien, Austria

Emeritus Research

🇦🇺

Camberwell, Victoria, Australia

St Vincents Hospital Melbourne

🇦🇺

Fitzroy, Victoria, Australia

AKH

🇦🇹

Wien, Austria

Helsinki University Hospital, HYKS

🇫🇮

Helsinki, Finland

Group de recherche en maladies osseuses

🇨🇦

Quebec, Canada

Hopital Ambroise Pare

🇧🇪

Mons, Belgium

Kiljava Medical Research

🇫🇮

Hyvinkaa, Finland

Terveystalo Kouvola

🇫🇮

Kouvola, Finland

SKiN Center for Dermatology

🇨🇦

Peterborough, Ontario, Canada

Frederiksberg Hospital

🇩🇰

Frederiksberg, Hovedstaden, Denmark

Aalborg Universitetshospital - Psykiatrien

🇩🇰

Aalborg, Denmark

Centre Hospitalier de Vendee Les Oudairies

🇫🇷

La Roche Sur Yon, France

Hôpital Pierre-Paul Riquet

🇫🇷

Toulouse cedex 9, France

Rheumazentrum Ratingen

🇩🇪

Ratingen, Nordrhein-Westfalen, Germany

Turun Yliopistollinen Keskussairaala

🇫🇮

Turku, Finland

HRF Hamburger Rheuma Forschungszentrum

🇩🇪

Hamburg, Germany

Klinikum der Universität München

🇩🇪

München, Bayern, Germany

Hôpital Trousseau, CHRU de Tours

🇫🇷

Chambray-lès-Tours, France

Hopital Edouard Herriot

🇫🇷

Lyon Cedex 03, France

Vital Medical Center

🇭🇺

Veszprem, Hungary

Artemis Hospital

🇮🇳

Gurgaon, Haryana, India

King George Hospital

🇮🇳

Visakhapatnam, Andhra Pradesh, India

Byramjee Jeejeebhoy Medical College & Civil Hospital

🇮🇳

Ahmedabad, Gujarat, India

Allergo-Derm Bakos Kft

🇭🇺

Szolnok, Jasz-Nagykun-Szolnok, Hungary

Kokilaben Dhirubhai Ambani Hospital &Medical Research Inst.

🇮🇳

Mumbai, Maharashtra, India

Obudai Egeszsegugyi Centrum Kft

🇭🇺

Budapest, Hungary

Care Hospital

🇮🇳

Hyderabad, Andhra Pradesh, India

UNO Medical Trials Kft.

🇭🇺

Budapest, Hungary

Panchshil Hospital

🇮🇳

Ahmedabad, Gujarat, India

Shalby Hospital

🇮🇳

Ahmedabad, Gujarat, India

Meir Medical Center

🇮🇱

Kfar Saba, Israel

CIMAB S.A. de C.V.

🇲🇽

Torreon, Coahuila, Mexico

Apollo Gleneagles Hospitals

🇮🇳

Kolkata, West Bengal, India

Centro Medico del Angel S.C.

🇲🇽

Mexicali, Baja California, Mexico

Carmel Medical Center

🇮🇱

Haifa, Israel

Assaf Harofeh Medical Center

🇮🇱

Zerifin, Israel

Presidio Ospedaliero Vittorio Emanuele

🇮🇹

Catania, Italy

Rabin Medical Center

🇮🇱

Petach Tikva, Israel

Istituto Ortopedico Rizzoli

🇮🇹

Bologna, Italy

Complesso Integrato Columbus

🇮🇹

Roma, Italy

Centro Investigacion de Tratam Innovadores de Sinaloa SC

🇲🇽

Culiacan, Sinaloa, Mexico

Fondazione Universitaria degli Studi G D'Annunzio

🇮🇹

Chieti, Italy

Ctro Inv en Artritis y Osteoporosis SC

🇲🇽

Mexicali, Baja California, Mexico

Grupo Médico CAMINO S.C.

🇲🇽

México City, Distrito Federal, Mexico

Clínica Enfermedades Crónicas y Procedimientos Especiales SC

🇲🇽

Morelia, Michoacan, Mexico

NZOZ Centrum Reumatologiczne Ind. Prak.

🇵🇱

Elblag, Poland

St Augustines Hospital

🇿🇦

Durban, South Africa

Cemdeicy S.C.P.

🇲🇽

Merida, Yucatán, Mexico

Suite 509 Umhlanga Netcare Medical Centre

🇿🇦

Durban, KwaZulu-Natal, South Africa

RM Pharma Specialists S.A. de C.V.

🇲🇽

Distrito Federal, Mexico

Twoja Przychodnia-Centrum Medyczne Nowa Sol

🇵🇱

Nowa Sol, Poland

Rheuma Medicus Zakład Opieki Zdrowotnej

🇵🇱

Warsaw, Poland

Greenacres Hospital

🇿🇦

Port Elizabeth, Eastern Cape, South Africa

Clinresco Centres (Pt) Ltd

🇿🇦

Johannesburg, Gauteng, South Africa

Antonius Ziekenhuis

🇳🇱

Sneek, Netherlands

Suite 209A Jakaranda Hospital

🇿🇦

Pretoria, South Africa

DermMEDICA Sp. z o.o.

🇵🇱

Wroclaw, Poland

Emmed Research

🇿🇦

Muckleneuk, South Africa

Winelands Medical Research Centre

🇿🇦

Stellenbosch, Western Cape, South Africa

Prof Ally

🇿🇦

Pretoria, South Africa

Hospital Marina Baixa

🇪🇸

La Vila Joiosa, Alicante, Spain

Hospital Infanta Luisa

🇪🇸

Sevilla, Spain

Regional Clinical Hospital Center for Emergency medical care

🇺🇦

Kharkiv, Ukraine

Hospital Del Sagrado Coraz

🇪🇸

Barcelona, Spain

Complexo Hospitalario Universitario A Coruña, CHUAC

🇪🇸

La Coruna, Spain

Kyiv City Clinical Hospital #3

🇺🇦

Kyiv, Ukraine

Multifield Medical Center of Odesa NMU (University Clinic#1)

🇺🇦

Odesa, Ukraine

Municipal Institution of Ternopil Regional Council

🇺🇦

Ternopil, Ukraine

Vinnytsya Regional Clinical Hospital

🇺🇦

Vinnytsya, Ukraine

Reumatologiska Kliniken Karolinska Universitetssjukhuset Solna

🇸🇪

Stockholm, Sweden

Southampton General Hospital

🇬🇧

Southampton, Hants, United Kingdom

National Scientific Center "Strazhesko institute of cardio"

🇺🇦

Kyiv, Ukraine

Regional Clinical Hospital of Zaporizhzhia

🇺🇦

Zaporizhzhia, Ukraine

The Great Western Hospital

🇬🇧

Swindon, Wiltshire, United Kingdom

Western General Hospital

🇬🇧

Edinburgh, Scotland, United Kingdom

Wythenshawe Hospital

🇬🇧

Wythenshawe, Manchester, United Kingdom

St Lukes Hospital

🇬🇧

Bradford, West Yorkshire, United Kingdom

The Dudley Group NHS Foundation Trust

🇬🇧

Dudley, West Midlands, United Kingdom

New Cross Hospital

🇬🇧

Wolverhampton, West Midlands, United Kingdom

Reumatologikliniken Västmanlands Sjukhus

🇸🇪

Västerås, Västmanland, Sweden

Istituto Clinico Humanitas

🇮🇹

Rozzano, Milano, Italy

Policlinico di Tor Vergata

🇮🇹

Roma, Italy

Ospedale Policlinico Giambattista Rossi, Borgo Roma

🇮🇹

Verona, Italy

North Tyneside General Hospital

🇬🇧

North Shields, Tyneside, United Kingdom

Centre de Recherche Musculo-Squelettique

🇨🇦

Trois-Rivieres, Quebec, Canada

Klinikum der Johann Wolfgang Goethe-Universität Frankfurt

🇩🇪

Frankfurt am Main, Hessen, Germany

Consultora Integral de Salud S.R.L.

🇦🇷

Cordoba, Argentina

Centro Medico Privado de Reumatologia

🇦🇷

San Miguel de Tucuman, Tucuman, Argentina

Centro de Medicina Familiar Mindout Research

🇦🇷

Ciudad Autonoma de Buenos Aire, Argentina

Reumatologiska Kliniken Skånes universitetssjukhus Malmö

🇸🇪

Malmo, Sweden

Centrum för reumatologi

🇸🇪

Stockholm, Sweden

Hospital Clinico Universitario de Santiago

🇪🇸

Santiago de Compostela, La Coruna, Spain

HUG-Hôpitaux Universitaires de Genève

🇨🇭

Genève, Switzerland

Polmed Research Inc.

🇨🇦

Saskatoon, Saskatchewan, Canada

© Copyright 2025. All Rights Reserved by MedPath